Skip to main content
OpenTrials
Completed

NCT Number: NCT07406386

Integrating Halotherapy Into Preseason Training Improves Respiratory and Aerobic Performance in Elite Female Soccer Players

This randomized controlled trial aimed to investigate the effects of a 12-week halotherapy intervention on respiratory muscle strength, pulmonary function, aerobic capacity, and intermittent running performance in elite female soccer players. Participants were randomly assigned to either a halotherapy group or a control group. Both groups followed the same preseason soccer training program, while the halotherapy group additionally received regular halotherapy sessions. Pre- and post-intervention assessments included spirometric measurements, respiratory muscle strength, estimated VO₂max, and Yo-Yo Intermittent Recovery Test Level 1 performance.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Gumushane Univetsity

Gümüşhane, Trabzon, Ordu, Giresun, Rize, Artvin, Gümüşhane, 29600, Turkey (Türkiye)

About this study

Aerobic capacity and respiratory efficiency are critical determinants of performance in elite soccer. Halotherapy, a non-pharmacological intervention involving inhalation of dry salt aerosol in a controlled environment, has been shown to improve pulmonary health in clinical populations; however, evidence in athletic populations remains limited.

This randomized parallel-group trial was conducted during the preseason period of the Turkish Women's First League. Twenty-eight elite female soccer players were randomly allocated to a halotherapy group or a control group. Both groups completed an identical 12-week soccer training program. In addition to training, the halotherapy group underwent 45-minute halotherapy sessions three times per week in a controlled halochamber environment.

Outcome measures included maximal inspiratory and expiratory pressures (MIP, MEP), pulmonary function parameters (FVC, FEV₁, PEF, MVV), aerobic capacity estimated via the Yo-Yo Intermittent Recovery Test Level 1, and total distance covered in the Yo-Yo test. Measurements were collected before and after the intervention period. The study aimed to determine whether halotherapy provides additive benefits to standard soccer training in elite female athletes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female soccer players aged 18-30 years
  • Competing in the Turkish Women's First League
  • Minimum of 5 years of competitive soccer experience
  • Regular training ≥10 hours per week
  • Free from injury at study entry
  • Non-smokers
  • Not using chronic medication
  • Provided written informed consent

Exclusion criteria

  • Presence of respiratory, cardiovascular, or metabolic disease
  • Current musculoskeletal injury
  • Smoking
  • Pregnancy
  • Use of medications affecting respiratory or cardiovascular function

Treatment and study plan

Halotherapy Group

Other

Participants followed the standard preseason soccer training program and additionally received halotherapy.

Halotherapy sessions were conducted in a controlled halochamber using a dry salt aerosol generator. Sessions lasted 45 minutes and were performed three times per week for 12 weeks. Aerosol concentration was maintained at approximately 20 mg/m³ with particle size <5 microns. Environmental conditions were controlled (temperature 20-24°C, humidity 40-60%).

Control

Other

Participants followed the same standard preseason soccer training program without halotherapy.

Primary outcomes

  1. Maximal Expiratory Pressure (MEP)

    Time frame: 12 week

    Expiratory muscle strength measured using a portable respiratory pressure meter.

  2. Maximal Inspiratory Pressure (MIP)

    Time frame: 12 week

    Inspiratory muscle strength measured using a portable respiratory pressure meter.

  3. Aerobic Capacity (VO₂max estimate)

    Time frame: 12 week

    VO₂max estimated using the Yo-Yo Intermittent Recovery Test Level 1.

Secondary outcomes

  1. Forced Vital Capacity (FVC)

    Time frame: 12 week

    Measured by spirometry.

  2. Forced Expiratory Volume in 1 Second (FEV₁)

    Time frame: 12 weeks

    Measured by spirometry.

  3. Peak Expiratory Flow (PEF)

    Time frame: 12 week

    Measured by spirometry.

  4. Yo-Yo Intermittent Recovery Test Level 1 Distance

    Time frame: 12 week

    VO₂max estimated using the Yo-Yo Intermittent Recovery Test Level 1.

Sponsors and collaborators

Lead sponsor

Gümüşhane Universıty

Other

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Feb 12, 2026
Registry last updated
Feb 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.